Loading clinical trials...
Loading clinical trials...
A Phase 1/2 Pharmacokinetic Multi-tumor Study of Subcutaneous Formulation of Ipilimumab Monotherapy and in Combination With Subcutaneous Nivolumab
Conditions
Interventions
ipilimumab
nivolumab
+2 more
Locations
6
United States
Local Institution - 0020
Hartford, Connecticut, United States
Local Institution - 0013
Fort Wayne, Indiana, United States
Istituto Nazionale Tumori IRCCS Fondazione Pascale-s.c. melanoma, immunoterapia oncologica e terapie
Naples, Italy
Humanitas-U.O di Oncologia medica ed Ematologia
Rozzano, Italy
ospedale le scotte-U.O.C. Immunoterapia Oncologica
Siena, Italy
Local Institution - 0010
Auckland, New Zealand
Start Date
June 25, 2020
Primary Completion Date
January 14, 2021
Completion Date
January 18, 2023
Last Updated
February 24, 2023
NCT05839379
NCT06898450
NCT00024804
NCT05720117
NCT01247597
NCT05128890
Lead Sponsor
Bristol-Myers Squibb
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions